Top of this page
Skip navigation, go straight to the content

Newsroom Press Releases

Transparency Declaration by Capital Research and Management Company (CRMC)

Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:

 

Participation on 1 September 2008 (transitional provision of the law of 2 May 2007 on the disclosure of large shareholdings).

 

Pursuant to the notification filed with the BFIC on 30 October 2008 (exemption set forth in article 21, §2 and 28 of the Royal Decree of 14 February 2008), Capital Research and Management Company (CRMC), with registered office at 333, South Hope Street, Los Angeles, Ca. 90071-1406, USA, has notified having voting discretion over a number of shares crossing the threshold of 10% of UCB's capital (21,717,895 shares on a total of 183,365,052 or 11.84%).

According to CRMC, the notification of this filing does not reflect an acquisition or disposition of shares, but rather CRMC's voting interest in shares of UCB under the Transparency Directive.

CRMC is an investment adviser and a 100% owned subsidiary of its parent company, The Capital Group (CGC). Neither CGC nor CRMC owns shares of Belgian issuers on their own behalf. Rather the shares reported in CRMC's notification are owned by mutual funds under the discretionary investment management of CRMC. Certain mutual funds managed by CRMC have delegated the right to vote the proxies of their portfolio securities to CRMC. By virtue of such delegation, CRMC holds voting interest in shares of UCB crossing the 10% threshold.

According to this notification, EuroPacific Growth Fund, with registered offices at 333, South Hope Street, Los Angeles, Ca. 90071-1406, USA is the person that disposes of these voting rights.

The declaration can be found on: https://www.ucb.com/investors/shares.asp

 

About UCB

UCB, Brussels, Belgium (www.ucb-group.com) is a global biopharmaceutical company dedicated to the research, development and commercialisation of innovative medicines focused on central nervous system and immunology disorders. Employing more than 10,000 people in over 40 countries, UCB achieved revenues of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB).


Stay up-to-date on the latest news and information from UCB